$0.165
-0.001 (-0.42%)Al cierre
Noticias de VTGN
Eventos de VTGN
Vistagen Collaborates with GATC Health to Advance Drug Development
Vistagen announced its collaboration with GATC Health, a tech-bio company applying artificial intelligence and multiomics to drug discovery and development. The collaboration brings GATC Health's proprietary Operon platform and Derisq report to Vistagen's lead clinical-stage programs. GATC Health uses its Operon platform and Derisq predictive intelligence capabilities to provide strategic insights for Vistagen's potential next Phase 3 study of fasedienol for treatment of social anxiety disorder with the Liebowitz Social Anxiety Scale as the primary efficacy endpoint, as well as potential Phase 2 studies of itruvone for major depressive disorder and refisolone for menopausal hot flashes. "We are incorporating key predictive insights from our collaboration with GATC Health into protocol development for our fasedienol program in social anxiety disorder, complementing our experience and existing datasets," said Shawn Singh, president and CEO of Vistagen.
Vistagen Presents Positive Data for Fasedienol Nasal Spray at Psych Congress 2026
Vistagen presented positive exploratory data at Psych Congress 2026 in New Orleans. The poster highlights a potential efficacy signal for fasedienol nasal spray, the Company's rapid-onset Phase 3 product candidate, observed in a public speaking challenge study involving participants with very severe social anxiety disorder. The research presented by Vistagen in a poster supports fasedienol's potential for individuals with very severe social anxiety disorder, as defined by a baseline Liebowitz Social Anxiety Scale score of 95 or higher. In subpopulation analyses, one post-hoc and one prespecified, from two randomized, double-blind, placebo-controlled clinical trials, participants with very severe social anxiety disorder experienced improvements in anxiety symptoms following treatment with fasedienol compared with placebo as measured by the Subjective Units of Distress Scale, SUDS.
Vistagen Reports Positive Preliminary Data from PALISADE-4 Study
Vistagen announced preliminary positive data from the open-label extension, OLE, portion of its PALISADE-4 Phase 3 study of fasedienol for the acute treatment of social anxiety disorder. In a recent analysis of subjects who elected to participate in the OLE portion of PALISADE-4, administration of 3.2 microgram of fasedienol, taken as needed up to six times per day in anxiety-provoking social and performance situations in everyday life for up to 12 months, was well-tolerated with no new drug-related safety findings. Exploratory efficacy data over the first four months of as-needed treatment demonstrated improvement over time on both the Liebowitz Social Anxiety Scale and the Social Phobia Inventory.
Vistagen Announces Phase 2 Results for Fasedienol Nasal Spray
Vistagen announced the topline results of its exploratory Phase 2 repeat dose study evaluating fasedienol nasal spray in adult subjects with social anxiety disorder. The three-arm, multicenter, randomized, double-blind, placebo controlled clinical study, which included an open label extension, was designed to assess the efficacy, safety, and tolerability of two 3.2 microgram doses of fasedienol administered ten minutes apart compared with a single 3.2 microgram dose and placebo, for the acute treatment of anxiety induced by a public speaking challenge. The study was not designed to demonstrate statistically significant differences between treatment groups. The exploratory study met its safety objective, demonstrating that a second dose administered within ten minutes of the first dose produced safety and tolerability data comparable to single-dose administration, with no new safety findings and overall safety findings consistent with previous clinical studies. In addition, both active treatment arms in the primary endpoint analysis, LS mean change in subjective units of distress score from Visit 2 to Visit 3, showed numerical separation from placebo, although the differences between treatment groups and placebo were not statistically significant. The primary efficacy results showed numerical separation from placebo in mean SUDS change from V2 to V3. In the prespecified analysis of patients with very severe social anxiety disorder as defined by a baseline Liebowitz Social Anxiety Scale score of greater than or equal to 95, fasedienol showed nominally statistically significant responses for the single dose arm compared with placebo and as pooled. The treatment effect for repeat dose fasedienol was numerically larger, although the smaller sample size and variability resulted in a higher p-value. The findings in the very severe group of patients defined by LSAS greater than or equal to 95 are consistent with results previously observed in the randomized portion of the company's PALISADE-4 Phase 3 trial for the acute treatment of social anxiety disorder, where in a post-hoc analysis of patients with very severe social anxiety defined by LSAS greater than or equal to 95, fasedienol also demonstrated a nominally statistically significant improvement compared with placebo. Responder rates for the Clinician Global Impression of Improvement and the Patient Global Impression of Change secondary endpoints were directionally higher for fasedienol than placebo, providing consistency across primary and secondary endpoints for the total population in the study. In addition, the fasedienol responder rates in the repeat dose arm were more than twice those observed with placebo. A prespecified exploratory analysis in V2 to V3 change of anticipatory anxiety prior to the beginning of the public speaking challenge showed a larger decrease in mean SUDS score for fasedienol compared with placebo, with the repeat dose and pooled fasedienol showing nominal statistical significance.
SRX Global Acquires Stake in Vistagen
SRX Global (SRXH) announced that it has acquired a stake in Vistagen (VTGN). The company said it views Vistagen shares as undervalued and welcomes constructive engagement with its leadership team and board of directors to discuss ideas on how to unlock shareholder value.
Artículos relacionados
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.